Drug makers in Canada are not collaborating with Florida on a plan to import cheaper medication, despite the state's government's insistence that such a program is in the works. This comes as a surprise, given the significant price differences between the U.S. and Canada for the same pharmaceutical products. Industry data reveals that U.S. prices are more than triple those in Canada, presenting a compelling case for the potential cost savings of importing drugs from the north.
Since 2019, Florida Governor Ron DeSantis has proposed that state drug plans could address the high price of pharmaceuticals by importing medication from Canada, where it is cheaper. Canadian manufacturers already sell about $7 billion worth of pharmaceutical products to the United States each year, and exporting some products at Canadian prices would essentially undercut the prices they are already charging in the U.S.
In 2024, the U.S. Food and Drug Administration approved Florida’s plan to import drugs, though only for two years. However, no drugs have yet been shipped through the program, despite the state opening a warehouse at a cost of more than $80 million. The site has since been used to house emergency equipment for hurricane season.
Canadian drug manufacturers and distributors have denied working with Florida on this program. Associations representing these industries have stated that they have not spoken to Florida about this initiative and are not aware of any distributors in talks with the state. The Canadian prices are cheaper due to the public healthcare system and different cost control methods used by Canadian regulators, making the proposed import program less effective in addressing high U.S. prices.
The plan also runs counter to other initiatives from the Trump administration to address pharmaceutical pricing and manufacturing. President Trump frequently threatened tariffs on pharmaceuticals, including a national-security investigation into the drug supply chain and the imposition of 100-per-cent tariffs on branded drugs made by companies without a manufacturing presence in the United States. However, these threats never materialized, and the administration has since focused on signing 'most-favored nation' agreements with drug makers, where they pledge to lower U.S. prices in exchange for better reimbursement through Medicare insurance plans.
